| Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations TF Eleveld, DA Oldridge, V Bernard, J Koster, LC Daage, SJ Diskin, ... Nature genetics 47 (8), 864-871, 2015 | 537 | 2015 |
| Neuroblastoma is composed of two super-enhancer-associated differentiation states T Van Groningen, J Koster, LJ Valentijn, DA Zwijnenburg, N Akogul, ... Nature genetics 49 (8), 1261-1266, 2017 | 427 | 2017 |
| TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors LJ Valentijn, J Koster, DA Zwijnenburg, NE Hasselt, P Van Sluis, ... Nature genetics 47 (12), 1411-1414, 2015 | 394 | 2015 |
| Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors J Wegert, N Ishaque, R Vardapour, C Geörg, Z Gu, M Bieg, B Ziegler, ... Cancer cell 27 (2), 298-311, 2015 | 314 | 2015 |
| An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity C Calandrini, F Schutgens, R Oka, T Margaritis, T Candelli, L Mathijsen, ... Nature communications 11 (1), 1310, 2020 | 215 | 2020 |
| Gain of 1q as a prognostic biomarker in Wilms tumors (WTs) treated with preoperative chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 trial: a … T Chagtai, C Zill, L Dainese, J Wegert, S Savola, S Popov, W Mifsud, ... Journal of Clinical Oncology 34 (26), 3195, 2016 | 127 | 2016 |
| The immune landscape of neuroblastoma: challenges and opportunities for novel therapeutic strategies in pediatric oncology J Wienke, MP Dierselhuis, GAM Tytgat, A Künkele, S Nierkens, ... European journal of cancer 144, 123-150, 2021 | 119 | 2021 |
| PHOX2B Is a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma J Stutterheim, A Gerritsen, L Zappeij-Kannegieter, I Kleijn, R Dee, L Hooft, ... Journal of clinical oncology 26 (33), 5443-5449, 2008 | 113 | 2008 |
| 123I‐MIBG scintigraphy and 18F‐FDG‐PET imaging for diagnosing neuroblastoma G Bleeker, GAM Tytgat, JA Adam, LCM Kremer, L Hooft, EC van Dalen Cochrane Database of Systematic Reviews, 2015 | 93 | 2015 |
| Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers J Stutterheim, A Gerritsen, L Zappeij-Kannegieter, B Yalcin, R Dee, ... Clinical chemistry 55 (7), 1316-1326, 2009 | 91 | 2009 |
| Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response … SA Burchill, K Beiske, H Shimada, PF Ambros, R Seeger, GAM Tytgat, ... Cancer 123 (7), 1095-1105, 2017 | 90 | 2017 |
| Catecholamines profiles at diagnosis: Increased diagnostic sensitivity and correlation with biological and clinical features in neuroblastoma patients IRN Verly, ABP van Kuilenburg, NGGM Abeling, SMI Goorden, M Fiocco, ... European journal of cancer 72, 235-243, 2017 | 83 | 2017 |
| Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma R Cuperus, R Leen, GAM Tytgat, HN Caron, ABP Van Kuilenburg Cellular and Molecular Life Sciences 67, 807-816, 2010 | 83 | 2010 |
| Development of a Real-Time Polymerase Chain Reaction Assay for Prediction of the Uptake of Meta-[131I]iodobenzylguanidine by Neuroblastoma Tumors S Carlin, RJ Mairs, AG McCluskey, DA Tweddle, A Sprigg, C Estlin, ... Clinical cancer research 9 (9), 3338-3344, 2003 | 71 | 2003 |
| The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review R Van Paemel, R Vlug, K De Preter, N Van Roy, F Speleman, L Willems, ... European journal of pediatrics 179, 191-202, 2020 | 53 | 2020 |
| Toxicity of upfront 131I-metaiodobenzylguanidine (131I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis G Bleeker, RA Schoot, HN Caron, J De Kraker, CA Hoefnagel, ... European journal of nuclear medicine and molecular imaging 40, 1711-1717, 2013 | 48 | 2013 |
| Upfront treatment of high‐risk neuroblastoma with a combination of 131I‐MIBG and topotecan KCJM Kraal, GAM Tytgat, BLF van Eck‐Smit, B Kam, HN Caron, ... Pediatric blood & cancer 62 (11), 1886-1891, 2015 | 43 | 2015 |
| Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma J Stutterheim, FA Ichou, E den Ouden, R Versteeg, HN Caron, GAM Tytgat, ... Clinical Cancer Research 18 (3), 808-814, 2012 | 42 | 2012 |
| Differentiated Thyroid Carcinoma After 131I-MIBG Treatment for Neuroblastoma During Childhood: Description of the First Two Cases HM van Santen, GAM Tytgat, MD van de Wetering, BLF van Eck-Smit, ... Thyroid 22 (6), 643-646, 2012 | 41 | 2012 |
| Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids OG Besançon, GAM Tytgat, R Meinsma, R Leen, J Hoebink, GV Kalayda, ... Cancer letters 319 (1), 23-30, 2012 | 39 | 2012 |
